The FDA issued an alert May 7 warning patients with certain implanted Medtronic pacemakers or cardiac resynchronization therapy pacemakers (CRT-Ps) and their care teams to check for premature battery depletion in their devices after defects resulted in three reports and one patient death.

Individuals with heart failure with preserved ejection fraction (HFpEF) and atrioventricular block might benefit more from cardiac resynchronization therapy (CRT) than conventional right ventricular (RV) pacing, according to research published in JACC: Heart Failure.

Cardiac abnormalities stemming from preterm birth can be corrected with a three-and-a-half-month exercise program in patients’ teens and twenties, according to a drug-free trial of Canadian adults.

A new biotech company out of Massachusetts is levering human genetics and genome editing to “turn the tide” of coronary artery disease (CAD), experimenting with CRISPR to stop CAD from ever developing in at-risk individuals.

The FDA has cleared two new drugs, tafamidis and tafamidis meglumine, for the treatment of cardiomyopathy caused by a rare disorder known as transthyretin-mediated amyloidosis (ATTR-CM).

The migraine medication galcanezumab might protect against adverse CV events in patients taking the drug for episodic headaches, according to research presented at the American Academy of Neurology’s 2019 meeting in Philadelphia.

Vivimed Life Sciences on May 3 announced a voluntary recall of 19 lots of losartan potassium tablets, making it the third company in two weeks to issue a recall of the blood pressure (BP) drug.

A Harvard cardiologist and his team have developed an experimental genetic test for predicting obesity, NPR reports.